HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve η1-N, η2-N,O, η1-O, and η6 bonding modes, via a novel N-π rearrangement; relative binding affinities and computer docking studies of cis and trans-η6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERα and ERβ receptors, and growth inhibition to breast cancer cells.

Abstract
The reactions of the breast cancer drug metabolite derivatives of tamoxifen, cis and trans-hydroxytamoxifen, cis-1 and trans-2, with [Cp*Rh(L)(3)](2+) complexes (L = H(2)O or MeOH), in CH(2)Cl(2) and CH(3)OH solvents, initially provided the kinetic η(1)-N complexes, cis-4 (OTf(-), CH(3)OH) and trans-5 (OTf(-), CH(3)OH), which underwent a novel, regioselective, intramolecular N-π rearrangement to give the cis and trans-η(6)-phenol substituted complexes, cis-6 and trans-7, via η(2)-N,O, η(1)-O, and ether aromatic ring η(6) intermediates. Recent density functional theory (DFT) calculations showed a preferred ground state for η(1)-N; η(2)-N,O; η(1)-O; and the η(6) complexes, including the prominent roles of the triflate anion (OTf(-)), and solvent molecules (CH(2)Cl(2) and CH(3)OH), and provided further steric, electronic, and thermodynamic data on the mechanism of the N-π rearrangement. The η(6) complex, cis-6, was shown to be an antagonist for ERα estrogen receptor binding, in a competition experiment with the female hormone, estradiol; therefore, computer docking studies of this biologically active complex at the estrogen receptors, ERα and ERβ, also provided information on the binding modes and thermodynamic parameters, while bioassay results provided growth inhibition data on both hormone dependent and independent breast cancer cell lines.
AuthorsSiden Top, Irena Efremenko, Marie Noelle Rager, Anne Vessières, Paul Yaswen, Gérard Jaouen, Richard H Fish
JournalInorganic chemistry (Inorg Chem) Vol. 50 Issue 1 Pg. 271-84 (Jan 03 2011) ISSN: 1520-510X [Electronic] United States
PMID21121684 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Estrogen Receptor alpha
  • Estrogen Receptor beta
  • Estrogens
  • Organometallic Compounds
  • Tamoxifen
  • afimoxifene
  • Rhodium
Topics
  • Antineoplastic Agents, Hormonal (chemical synthesis, pharmacology)
  • Breast Neoplasms (drug therapy)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Estrogen Receptor alpha (antagonists & inhibitors, metabolism)
  • Estrogen Receptor beta (antagonists & inhibitors, metabolism)
  • Estrogens (metabolism)
  • Female
  • Humans
  • Models, Molecular
  • Organometallic Compounds (chemical synthesis, pharmacology)
  • Protein Binding
  • Rhodium (chemistry)
  • Stereoisomerism
  • Tamoxifen (analogs & derivatives, chemistry, pharmacology)
  • Thermodynamics

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: